A Phase I Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer following modified FOLFIRINOX

Publication date: Available online 24 May 2016
Source:International Journal of Radiation Oncology*Biology*Physics
Author(s): Walid L. Shaib, Natalyn Hawk, Richard J. Cassidy, Zhengjia Chen, Chao Zhang, Edith Brutcher, David Kooby, Shishir K. Maithel, Juan M. Sarmiento, Jerome Landry, Bassel F. El-Rayes
In borderline resectable pancreatic cancer management, high rates of positive posterior margin (PM) are reported. Stereotactic body radiation therapy (SBRT) allows higher radiation doses. SBRT escalation dose was evaluated in a single institution, 3+3 phase I clinical trial delivered after 2 cycles of modified FOLFIRINOX. We planned 4 dose levels (DL) delivered in 3 fractions. DL-4 (45 Gy included 9 Gy to PM) was safe. Further dose escalations are needed.



from Cancer via ola Kala on Inoreader http://ift.tt/1sPCZTx
via IFTTT